Novel Protein Carrier Boosts Paclitaxel Solubility 3,600-Fold in Targeted Cancer Therapy
核心洞察
Researchers at Osaka Metropolitan University developed a novel drug delivery system using lipocalin-type prostaglandin D synthase (搜索) (L-PGDS (搜索)) enzyme as a carrier for paclitaxel, improving the anticancer drug's solubility by approximately 3,600-fold compared to phosphate-buffered saline suspension.
The team enhanced the system by attaching CRGDK (搜索) targeting peptide to create L-PGDS (搜索)-CRGDK, which binds to neuropilin-1 (搜索) receptors on cancer (搜索) cell surfaces for selective delivery to tumor tissues.
In mouse models with MDA-MB-231 breast cancer (搜索) cells, the PTX/L-PGDS (搜索)-CRGDK (搜索) formulation demonstrated superior and sustained antitumor effects that persisted even after treatment cessation, outperforming commercially available paclitaxel formulations.
Researchers at Osaka Metropolitan University have developed a breakthrough drug delivery system that dramatically improves the therapeutic potential of paclitaxel, a widely used but problematic anticancer drug. The novel approach uses a protein carrier to increase paclitaxel's water solubility by approximately 3,600-fold while enabling targeted delivery to cancer (搜索) cells.
The research, led by Professor Takashi Inui from the Graduate School of Agriculture, addresses a critical challenge in modern cancer (搜索) therapy: many promising drug candidates possess poor water solubility and large molecular weights that limit their absorption and therapeutic effectiveness while causing severe side effects in healthy tissues.
Protein Carrier Transforms Drug Solubility
The team utilized lipocalin-type prostaglandin D synthase (搜索) (L-PGDS (搜索)) enzyme as a novel carrier for paclitaxel, an anticancer drug with poor water solubility and a molecular weight of 854. Through docking simulations and solubility testing, researchers discovered that paclitaxel binds primarily via hydrophobic interactions to the upper region of the L-PGDS β-barrel protein structure.
This binding mechanism resulted in a remarkable improvement in drug solubility—approximately 3,600-fold compared to when paclitaxel is suspended in phosphate-buffered saline. The dramatic enhancement addresses one of the primary obstacles preventing effective delivery of this potent anticancer agent.
Targeted Delivery Through Receptor Binding
To enhance cancer (搜索) cell specificity, the researchers engineered a modified version by attaching the targeting peptide CRGDK (搜索) to the C-terminus of L-PGDS (搜索), creating L-PGDS-CRGDK. This peptide specifically binds to the neuropilin-1 (搜索) receptor, which is commonly expressed on cancer cell surfaces, enabling selective delivery to tumor tissues while potentially reducing systemic toxicity.
Superior Performance in Preclinical Testing
The effectiveness of the new delivery system was evaluated using a mouse model implanted with MDA-MB-231 breast cancer (搜索) cells. The results demonstrated clear advantages over existing formulations. While commercially available paclitaxel showed antitumor effects during the administration period, these effects weakened after treatment cessation.
In contrast, both PTX/L-PGDS (搜索) and PTX/L-PGDS-CRGDK (搜索) maintained antitumor effects even after administration ended. Most notably, PTX/L-PGDS-CRGDK exhibited the highest tumor suppression effect among all tested formulations, suggesting that the combination of improved solubility and targeted delivery provides synergistic benefits.
Implications for Cancer Drug Development
The findings, published in ACS Omega, demonstrate that L-PGDS (搜索) can effectively bind relatively large drugs with molecular weights up to approximately 850. This capability extends beyond paclitaxel to potentially include other challenging anticancer compounds that share similar physicochemical properties.
"This study demonstrated that L-PGDS (搜索) can bind relatively large drugs with molecular weights up to approximately 850 and further revealed that introducing a targeting peptide enables the selective delivery of anticancer drugs to cancer (搜索) cells," stated Professor Inui. "The DDS developed in this study is anticipated to significantly contribute to the advancement of future cancer treatments as a novel delivery strategy for poorly soluble anticancer drugs."
The research addresses a widespread problem in pharmaceutical development, where numerous drug candidates with high therapeutic efficacy remain difficult to translate into effective treatments due to poor solubility and distribution challenges. The L-PGDS (搜索)-based delivery system offers a potential solution that could be adapted for various poorly soluble anticancer drugs, potentially expanding the arsenal of effective cancer (搜索) therapies while reducing treatment-related toxicities.